H istorically, the standard treatment for the acute management and prophylaxis of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), has been unfractionated heparin (UFH). However, UFH has a number of pharmacokinetic and Low molecular weight heparins are replacing unfractionated heparin in a number of clinical indications because of their improved subcutaneous bioavailability and more predictable antithrombotic response. Clinical trials have demonstrated that low molecular weight heparins are at least as safe and effective as unfractionated heparin for the initial treatment of venous thromboembolism, and unfractionated heparin and warfarin for primary and secondary thromboprophylaxis. The mechanism behind the antithrombotic action of low molecular weight heparins is not fully understood but is likely to involve inhibition of coagulation factors Xa and IIa (thrombin), release of tissuefactor-pathway inhibitor, and inhibition of thrombin activatable fibrinolytic inhibitor. Different low molecular weight heparins have been shown to have various effects on coagulation parameters. Seven low molecular weight heparins are currently marketed worldwide, each demonstrated distinct chemical entities with unique pharmacokinetic and pharmacodynamic profiles. Each low molecular weight heparin is approved for specific indications based on the available efficacy and safety data for that product. The relative efficacy and safety of the low molecular weight heparins are unclear because there have been very few direct comparisons in randomized clinical trials. While recommending low molecular weight heparins for the prevention and treatment of venous thromboembolism, clinical guidelines have not specified individual agents. National and international organizations recognize that low molecular weight heparins are distinct entities and that they should not be used interchangeably in clinical practice. Each low molecular weight heparin should be used at the recommended dose when efficacy and safety data exist for the condition being treated. When these data are not available, the dosing and administration of low molecular weight heparins must be adapted from existing data and recommendations.
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subcutaneous administration and have greater bioavailability, longer half-lives (t 1/2 ), a more predictable dose response, and a potentially improved safety profile. 1, 3 Low molecular weight heparins have been shown to be effective and well-tolerated alternatives to UFH in treating and preventing VTE. [4] [5] [6] [7] [8] [9] Laboratory monitoring of coagulation status is not generally required with LMWH therapy, except in patients with renal insufficiency. 10 Branded LMWHs currently available in the United States include dalteparin, enoxaparin, and tinzaparin. Additional products available in Europe and in other countries include certoparin, nadroparin, parnaparin, and reviparin. 11 Although the various LMWHs have many properties in common, they all have their differences. Each LMWH is prepared by a different method and is chemically unique. 12 The relative efficacy and safety of individual LMWHs are unclear because very few well-designed trials have directly compared different branded products.
There has been much discussion about whether the different LMWHs can be used interchangeably in clinical practice for various indications. Clarification of this issue will only come by continuing to review their pharmacology and the clinical role of LMWHs in the management of VTE in the light of new data.
Pharmacology of LMWHs
Unfractionated heparin is a heterogenous mixture of polysaccharide chains with molecular weights ranging from 3000 to 30 000 daltons (Da). 13, 14 Low molecular weight heparins are derived from heparin by either enzymatic or chemical depolymerization to produce oligosaccharide chains of various lengths. 3 The fragments are approximately one third of the size of heparin, with mean molecular weights of 4300 Da to 5800 Da (Table 1) , and a molecular weight distribution of 1000 Da to 10 000 Da. 1 The different depolymerization procedures used to prepare LMWHs cause additional structural differences that affect the characteristics of the product. 15, 16 For example, certoparin, dalteparin, nadroparin, and reviparin are prepared by nitrous acid depolymerization, and enoxaparin by benzylation followed by alkaline hydrolysis, and tinzaparin by heparinase digestion. As a result, these different processes produce molecular and structural changes in LMWHs that are characteristics of the process. 16 Because of the differences in molecular composition and structure, each LMWH is unique and differs from other LMWHs in its biochemical, physicochemical, pharmacological, and clinical profiles. 16 Low molecular weight heparins exhibit a more predictable anticoagulant response than UFH due to reduced binding to plasma proteins, and a longer plasma t 1/2 as a result of reduced binding to macrophages and endothelial cells. 1, 17 This means that body weight-adjusted doses of LMWHs can be administered subcutaneously, once or twice daily, without monitoring of coagulation status in the majority of patients. 18 Thrombin (factor IIa) plays a pivotal role in the coagulation cascade. 19 The anticoagulant effect of heparin is mediated largely through binding of a unique pentasaccharide sequence to antithrombin. 1, 14 This results in a conformational change in antithrombin that facilitates binding to, and inactivation of, factor Xa. Heparin also catalyzes the inactivation of thrombin by antithrombin through binding both the enzyme and the inhibitor to form a ternary complex. Low molecular weight heparins are less able than UFH to bind thrombin because of their smaller molecular size, but they retain the ability to inactivate factor Xa. 20 This results in LMWHs exhibiting a higher ratio of inhibitory activity toward factor Xa versus factor IIa, referred to as the antiXa:anti-IIa ratio. While the anti-Xa:anti-IIa ratio of UFH is 1:1, the ratios for LMWHs range from 2.2 to 4.1 (Table 1) , depending on their molecular size distribution. 15 A phase I bioequivalence study has compared the anti-Xa and anti-IIa activities of 3 LMWHs (dalteparin, enoxaparin, and tinzaparin) using UFH as a reference drug. 21 The 3 LMWHs exhibited differences in ex vivo potency based on anti-Xa and anti-IIa activities, particularly with regard to anti-IIa activity.
Low molecular weight heparins are often characterized according to their anti-Xa and anti-IIa potencies. However, the relative importance of these effects to the inhibition of thrombosis is unclear since, at equivalent anti-Xa activities, the anti-IIa activity of different LMWHs varies markedly. 15 The mechanism of action of LMWHs is not yet fully understood, and the way in which LMWHs exert their anticoagulant effect is probably not limited to inhibition of factor Xa and thrombin. 22 Although anti-Xa activity has been adopted by the European Pharmacopoeial Commission as a measure of LMWH potency, 12 it represents only one of several properties of LMWHs that may contribute to their antithrombotic activity and does not predict therapeutic efficacy. 23 As there is no standardized method of determining equivalent antithrombotic doses of different LMWHs, clinical results are the only reliable guide to the appropriate dosage of individual agents. 24 Tissue-factor-pathway inhibitor (TFPI) may also contribute to the antithrombotic action of LMWHs and is the major regulator of tissue factor-induced coagulation. [25] [26] [27] Release of TFPI by LMWHs may, at least in part, explain why patients remain in an antithrombotic state for some hours after prophylactic doses of LMWH when anti-Xa activity is no longer detectable. 15 Low molecular weight heparins have also been shown to cause endogenous release of von Willebrand factor (vWF), which plays an important role in platelet aggregation. 16 Different LMWHs may result in varying release of TFPI and vWF, 28 although not all studies have found a difference. 29 Low molecular weight heparins have been associated with fibrinolytic effects, arising from modulation of the activity of thrombin activatable fibrinolytic inhibitor (TAFI). 16 Following activation by the thrombin/thrombomodulin complex, TAFI produces a molecular change in fibrin, making it resistant to lysis by plasmin. Since LMWHs are able to inhibit thrombin, they can modulate the thrombin-mediated activation of TAFI. Individual LMWHs have been shown to differ in the extent to which they inhibit the activity of TAFI. 16 Low molecular weight heparins also differ in respect to their antiproliferative effects on vascular endothelial cells 30 and their susceptibility to enzymatic degradation by heparinases. 16 Clearly, each LMWH is a distinct chemical entity with unique characteristics and a different overall pharmacological action. 16 Despite the large number of differences in laboratory measurements that have been described for the LMWHs, it is not clear how these differences influence their clinical effects. 23 The LMWHs exhibit complex interactions with endogenous proteins and cellular components. Recently, regulatory bodies have required submission of data on the immunogenic potential of various LMWHs. Since the molecular composition of these drugs varies, the relative interaction between the oligosaccharide components and platelet factor 4-related proteins results in the formation of neoepitopes, which may result in a differential generation of antibodies. While in most cases these antibodies are not pathogenic, they may have some effect on clinical outcomes in patients treated with LMWHs. It is likely that different LMWHs produce different types of antibodies. Similarly, other complex biologic interactions may result in differential responses at various levels.
LMWHs in the Treatment and Prevention of VTE
Low molecular weight heparins have been developed and are now replacing UFH for many clinical indications, in particular the treatment and prevention of DVT and PE.
Treatment of Acute VTE
For many years UFH was the standard initial treatment for acute VTE. However, recently there has been increasing use of LMWHs instead of UFH in the acute management of DVT. The findings of clinical trials and large meta-analyses show that nonmonitored, body weight-adjusted subcutaneous LMWH therapy is at least as effective and well tolerated as UFH administered by continuous infusion in patients with acute VTE. [4] [5] [6] 9, 31 The latest Cochrane review on this subject and a recent systematic review have both concluded that LMWHs are more effective than UFH for the initial treatment of VTE and significantly reduce the occurrence of major bleeding during initial therapy and mortality during follow-up. 9, 32 Identification of clinical differences between LMWHs has been limited because of the lack of direct comparisons in randomized clinical trials. Evaluations have been based largely on individual noncomparative trials, which differ in diagnostic methods, dosages and drug treatment schedules, and outcome measurements. 33 A randomized, singleblind trial comparing dalteparin (200 anti-Xa IU/kg once daily for ≥5 days) with tinzaparin (175 anti-Xa IU/kg once daily for ≥5 days) in 505 outpatients with acute VTE receiving concomitant warfarin therapy demonstrated that both LMWHs were safe and effective and showed no differences between them in terms of recurrence of VTE or bleeding. 34 Metaanalyzes of clinical trials comparing LMWHs with UFH have not revealed significant variation in clinical efficacy between the different LMWHs. 5, 6 However, some evidence suggests that individual LMWHs differ in terms of clinical safety in specific indications. One meta-analysis comparing LMWHs with UFH in the treatment of acute DVT indicated that dalteparin, nadroparin, and tinzaparin were associated with a lower risk of major bleeding than enoxaparin and reviparin. 5 A review of 16 studies with 7 different LMWHs used meta-regression analysis to compare the efficacy and safety of the LMWHs in the initial treatment of VTE.
14 The multivariate regression method statistically adjusted for potential confounders such as the LMWH used. Some differences between individual drugs were observed. Notably, dalteparin was associated with a significantly lower risk of major hemorrhage compared with the other LMWHs. However, dalteparin was also associated with a higher risk of recurrent VTE, which the authors suggest may be related to the dose of dalteparin used in the studies. It is likely that some of the differences observed during clinical use of different LMWHs may simply be a reflection of differences in study populations and administered doses.
Although clinical guidelines recommend the use of LMWHs for the initial treatment of VTE, the lack of direct comparative data has prevented the recommendation of one LMWH over another. 18, 35 The recent guidelines on the prevention and treatment of VTE issued by the International Union of Angiology (IUA) state that LMWHs should not be used interchangeably, and that the choice of LMWH should reflect the level of available clinical evidence.
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Long-Term Prophylaxis After Acute VTE
After acute DVT, there is a high risk of extension of thrombosis or recurrence of VTE, with the frequency estimated at 15% to 50%. 18 For this reason, extended thromboprophylaxis is recommended. 18 The standard approach involves the use of orally administered vitamin K antagonists, generally warfarin. However, 3 clinical trials have demonstrated that long-term treatment with LMWH for 3 to 6 months is at least as effectiveas-and in cancer patients is more effective than-warfarin for preventing recurrent VTE.
37-40 A 3-month regimen of once-daily tinzaparin at a dose of 175 anti-Xa IU/kg body weight has been evaluated in 2 randomized trials of long-term prophylaxis. 37, 38 In both of these trials, for which overall findings have only been published in abstracts, the LMWH regimen was as effective as warfarin-based regimens in the prevention of recurrent VTE. In a further analysis of one of the studies in which patients with cancer were stratified before randomization, tinzaparin was found to be more effective than a regimen of UFH for 5 days followed by long-term warfarin among cancer patients. 38, 39 Cancer patients with VTE have a greater than 3-fold higher risk of recurrent VTE than patients with VTE who do not have cancer. 41 Multiple factors are believed to contribute to this increased risk, including disease-related changes in hemostatic parameters and cancer therapies. 42 40 This is the first large-scale trial to specifically evaluate long-term prophylaxis with an LMWH in patients with cancer. Patients received either once-daily dalteparin 200 anti-Xa IU/kg body weight subcutaneously for 5 to 7 days and a vitamin K antagonist (warfarin or acenocoumarol) for 6 months or dalteparin alone for 6 months. The dalteparinonly arm received a new LMWH-dosing regimen designed to provide intensive initial anticoagulation (dalteparin 200 anti-Xa IU/kg once daily for 1 month) followed by a period of reduced-dose therapy (150 anti-Xa IU/kg once daily for 5 months) to minimize the long-term risk of bleeding. The risk of symptomatic, recurrent VTE was found to be significantly lower in patients with active cancer who received dalteparin than in those who received oral anticoagulant therapy (8.8% vs 17.4%; P = .002), with no increase in the risk of bleeding. The observation that the efficacy advantage of dalteparin was achieved without increasing the risk of bleeding is likely to reflect the specific dalteparin-dosing regimen used in the study.
In view of the findings of these trials, the latest guidelines published by the American College of Chest Physicians (ACCP) recommend that longterm anticoagulant therapy for patients with VTE and cancer should involve either dalteparin or tinzaparin at the doses used in the respective clinical trials. 18 More recently, the IUA guidelines recommend the use of LMWH for the initial treatment of cancer patients, and specify the dalteparin regimen used in the CLOT study (200 anti-Xa IU/kg once daily for 1 month, followed by 150 anti-Xa IU/kg once daily for 5 months) for the prevention of recurrent VTE.
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Primary Prevention of VTE
Low molecular weight heparins are used in a variety of clinical situations where the risk of VTE is high. 44 They are recommended for thromboprophylaxis in patients who have undergone major surgery, including abdominal, vascular, gynecological, neurological, and orthopedic surgery, as well as in trauma patients, cancer patients, and acutely ill medical patients in the presence of additional risk factors for VTE (eg, immobility, advanced age, prior VTE). 36, 45 There have been few direct comparative trials of LMWHs for primary prophylaxis. Once-daily subcutaneous injections of reviparin (4200 anti-Xa IU) and enoxaparin (4000 anti-Xa IU) have been compared in a large, multicenter, randomized trial of patients (N = 498) undergoing total hip replacement. 46 Administration of both drugs was commenced 10 to 12 hours before surgery and continued until efficacy was assessed by bilateral venography 10 to 14 days postoperatively. The drugs showed equivalent efficacy. Patients receiving reviparin showed a trend toward less bruising and fewer hematomas compared with patients receiving enoxaparin. A similar study in 499 patients undergoing total hip replacement, comparing once-daily subcutaneous injections of tinzaparin (4500 anti-Xa IU) and enoxaparin (4000 anti-Xa IU), demonstrated equivalent efficacy and safety for the 2 drugs. 47 A smaller randomized trial (N = 197) evaluated prophylaxis with dalteparin versus enoxaparin in patients undergoing hip fracture surgery. 48 Patients received dalteparin (2500 anti-Xa IU) or enoxaparin (2000 anti-Xa IU) preoperatively, and larger daily doses (dalteparin 5000 anti-Xa IU or enoxaparin 4000 anti-Xa IU) postoperatively until venography was performed 9 to 11 days after surgery. Again, no difference in efficacy or safety was found between the 2 drugs.
Meta-analyses of clinical trial data from patients undergoing surgery support the efficacy and safety of LMWHs for prevention of postoperative VTE and suggest that LMWHs are at least as effective and well tolerated as UFH. 7, 8, [49] [50] [51] However, no conclusions have been drawn concerning the relative benefits of individual LMWHs. The clinical outcomes appear to be highly dose-dependent, with larger doses of LMWH being associated with increased frequencies of bleeding. 7, 8 These observations indicate that the dose and dosing schedule of the individual drugs are important factors to consider in any analysis of clinical differences between LMWHs.
Conclusion
Because of their many common (class) characteristics, the LMWHs are often considered as members of a group of interchangeable drugs and are referred to generically, without reference to individual agents. Due to different depolymerization processes involved in their production, however, the LMWHs are distinct agents, each having a unique physical and chemical composition that leads to differences in biological actions. Many organizations, including the United States Food and Drug Administration (FDA), the European Medicine Evaluation Agency (EMEA), and the World Health Organization (WHO), classify each LMWH as a distinct drug. 16, 52 In the latest ACCP recommendations, individual LMWHs, such as dalteparin, have been specified based on evidence from large clinical trials. 17 Each LMWH has been evaluated in clinical trials for specific indications, and optimized dosages derived from these trials have received regulatory approval. While different LMWHs may be interchangeable at clinically optimized/approved dosages, these agents are not interchangeable at equivalent anti-Xa dosages. 23 Even at optimized dosages, the clinical profile of each LMWH may be different. Furthermore, meta-analyses suggest that LMWHs may differ in terms of bleeding risk. The relative efficacy and safety of LMWHs in the treatment and prevention of VTE remain unclear because there have been very few direct comparisons of these agents in welldesigned clinical trials. In the absence of comparative studies, clinical results for one LMWH should not be extrapolated to another. Each LMWH should be used at the recommended doses when efficacy and safety data exist for the condition being treated. When these data are not available, for example, for pregnancy, the dosing and administration of LMWHs must be adapted from existing data and recommendations.
Low molecular weight heparins are complex biological drug products of comparable molecular weight but with individual biological, pharmacological, and clinical characteristics. Potency adjustments of these complex drugs, based solely on anti-Xa and anti-IIa, do not minimize the variations between the LMWHs. Similarly, new antithrombotic agents 53, 54 should be differentiated from the LMWHs on the basis of product quality, mechanism of drug antithrombotic activity, pharmacological behavior, and clinical safety and efficacy.
Despite the development of several newer monotherapeutic agents such as the anti-Xa, antiIIa, and recombinant protein inhibitors, LMWHs remain the treatment of choice for VTE management. Thrombosis is a polypathologic syndrome and can be best managed by polytherapeutic drugs such as LMWHs.
Epilogue
Earlier this year several reports on increased incidents of adverse events and deaths with the use of UFH prompted the USFDA to intervene and investigate this matter. As a result, a contaminant namely, hypersufated chondroitin sulfate was identified and the adverse reactions were attributed to its presence. 55 The presence of this contaminant had a global impact and many other countries around the world also recalled unfractionated heparin due to the presence of this contaminant. 56 Since the LMWHs are produced by using UFH, the presence of this contaminant was also found in some of the commercial branded and generic LMWHs. The presence of such a contaminant in the LMWHs may alter their pharmacologic and immunogenic profile. Therefore, all of the LMWHs should be checked for the presence of this contaminant.
